Chemomab Therapeutics (CMMB) Assets Average (2019 - 2025)

Chemomab Therapeutics (CMMB) has 7 years of Assets Average data on file, last reported at $13.1 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average fell 30.85% year-over-year to $13.1 million; the trailing twelve-month figure through Dec 2025 stood at $13.1 million (down 30.85% YoY), and the FY2025 full-year result was $15.4 million, down 21.32% from the prior year.
• Assets Average for Q4 2025 stood at $13.1 million, up from $11.7 million in the prior quarter.
• Across five years, Assets Average topped out at $69.0 million in Q3 2021 and bottomed at $11.7 million in Q3 2025.
• The 5-year median for Assets Average is $29.0 million (2023), against an average of $35.1 million.
• The widest annual swing landed in 2021, when Assets Average jumped 679.2%; it then plunged 51.15% in 2023.
• A 5-year view of Assets Average shows it stood at $65.9 million in 2021, then declined by 29.22% to $46.6 million in 2022, then sank by 51.15% to $22.8 million in 2023, then retreated by 16.92% to $18.9 million in 2024, then plunged by 30.85% to $13.1 million in 2025.
• The last three Assets Average figures came in at $13.1 million (Q4 2025), $11.7 million (Q3 2025), and $12.0 million (Q2 2025), per Business Quant data.

Peer Comparison